Binding of bismuth to serum proteins: implication for targets of Bi(III) in blood plasma.
Bismuth complexes have been widely used in clinical treatment as antiulcer drugs. However, different adverse effects have been observed and the diagnosis is generally confirmed by the detection of bismuth in blood or blood plasma. In this study, binding of bismuth to human serum albumin was studied by fluorescence spectroscopy with the binding constant logK(a) to be 11.2. Competitive binding of bismuth to human albumin and transferrin was carried out at pH 7.4 by FPLC and ICP-MS. It was found that over 70% of bismuth binds to transferrin even in the presence of a large excess of albumin (albumin/transferrin=13:1) at pH 7.4, 10 mM bicarbonate. The distribution of bismuth between the two proteins was almost unchanged when Cys(34) of albumin was blocked. However, all bismuth binds to albumin when iron-saturated transferrin was used. Almost all of the bismuth was distributed over the fractions containing transferrin (70%) and albumin (<30%) in serum. The percentage of bismuth associated with transferrin was further increased by 15% with elevated transferrin in serum. Binding of bismuth to transferrin is much stronger than human albumin. Transferrin is probably the major target of bismuth in blood plasma, and it may play a role in the pharmacology of bismuth.
Sun
Hongzhe
H
Department of Chemistry and Open Laboratory of Chemical Laboratory, University of Hong Kong, Pokfulam Road, Hong Kong, PR China. hsun@hkucc.hku.hk
Szeto
Ka Yee
KY
D001729:Bismuth / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism*; D002850:Chromatography, Gel; D002852:Chromatography, Ion Exchange; D006801:Humans; D011485:Protein Binding; D013050:Spectrometry, Fluorescence
D001798:Blood Proteins; D001729:Bismuth